JO3388B1 - تركيبة دوائية ثابتة للإعطاء عن طريق الفم تضم ليفوسيتيريزين أو ملح منه مقبول دوائياً، و منتولوكاست أو ملح منه مقبول دوائياً - Google Patents

تركيبة دوائية ثابتة للإعطاء عن طريق الفم تضم ليفوسيتيريزين أو ملح منه مقبول دوائياً، و منتولوكاست أو ملح منه مقبول دوائياً

Info

Publication number
JO3388B1
JO3388B1 JOP/2013/0004A JOP20130004A JO3388B1 JO 3388 B1 JO3388 B1 JO 3388B1 JO P20130004 A JOP20130004 A JO P20130004A JO 3388 B1 JO3388 B1 JO 3388B1
Authority
JO
Jordan
Prior art keywords
pharmaceutically acceptable
acceptable salt
levocetirizine
montelukast
pharmaceutical formulation
Prior art date
Application number
JOP/2013/0004A
Other languages
English (en)
Inventor
Kwan Kwon Taek
Hyun Park Jae
Soo Woo Jong
Ho Kim Dong
Soo Kim Kyeong
Ii Kim Yong
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48745292&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3388(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Application granted granted Critical
Publication of JO3388B1 publication Critical patent/JO3388B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

يتعلق الإختراع الحالي بتركيبة دوائية تعطى بالفم لتثبيط أو علاج التهاب الأنف الأرجي أو داء الربو، وتشتمل على: (أ) جزء جسيمات أولى تشتمل على الليفوسيتريزين أو ملح منه مقبول دوائياً وحمض عضوي، و(ب) جزء جسيمات ثاني يشتمل على المونتيلوكاست أو ملح منه مقبول دوائياً. وتشتمل التركيبة الدوائية وفقاً للإختراع الحالي على حمض عضوي كعامل إستقرار والتي يمكن أن يثبط بشكل فعال المركب من المواد التقعلقة بالليفوسيتريزين والمونتيلوكاست وبالتالي، يظهر هذا المركب إسقرارية جيدة
JOP/2013/0004A 2012-01-06 2013-01-03 تركيبة دوائية ثابتة للإعطاء عن طريق الفم تضم ليفوسيتيريزين أو ملح منه مقبول دوائياً، و منتولوكاست أو ملح منه مقبول دوائياً JO3388B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020120001954A KR101418404B1 (ko) 2012-01-06 2012-01-06 레보세티리진 또는 이의 약학적으로 허용가능한 염 및 몬테루카스트 또는 이의 약학적으로 허용가능한 염을 함유하는 안정한 경구투여용 약학 제제

Publications (1)

Publication Number Publication Date
JO3388B1 true JO3388B1 (ar) 2019-03-13

Family

ID=48745292

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2013/0004A JO3388B1 (ar) 2012-01-06 2013-01-03 تركيبة دوائية ثابتة للإعطاء عن طريق الفم تضم ليفوسيتيريزين أو ملح منه مقبول دوائياً، و منتولوكاست أو ملح منه مقبول دوائياً

Country Status (20)

Country Link
US (1) US9486528B2 (ar)
EP (1) EP2800558B1 (ar)
JP (1) JP6163165B2 (ar)
KR (1) KR101418404B1 (ar)
CN (1) CN104039314B (ar)
AR (1) AR089666A1 (ar)
BR (1) BR112014016472B1 (ar)
ES (1) ES2671428T3 (ar)
JO (1) JO3388B1 (ar)
MX (1) MX354073B (ar)
PH (1) PH12014501545B1 (ar)
PL (1) PL2800558T3 (ar)
PT (1) PT2800558T (ar)
RU (1) RU2614382C2 (ar)
SG (1) SG11201403811VA (ar)
SI (1) SI2800558T1 (ar)
TR (1) TR201807978T4 (ar)
TW (1) TWI565482B (ar)
WO (1) WO2013103262A1 (ar)
ZA (1) ZA201405756B (ar)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6488003B2 (ja) * 2014-04-25 2019-03-20 アールピー シーラー テクノロジーズ リミテッド ライアビリティ カンパニー 安定なモンテルカスト溶液
KR101669556B1 (ko) * 2014-07-02 2016-10-28 한미약품 주식회사 몬테루카스트 또는 이의 약제학적으로 허용가능한 염의 경구투여용 액상제제
JP6575031B2 (ja) * 2014-07-28 2019-09-18 日本ケミファ株式会社 モンテルカストナトリウム製剤
RU2580303C1 (ru) * 2015-02-18 2016-04-10 Общество с ограниченной ответственностью "ПРОФИТ ФАРМ" Состав таблетированной формы лекарственного средства с действующим веществом пророксан
EP3222279B1 (en) 2016-03-21 2021-11-17 Invest Bielany Spolka z ograniczona odpowiedzialnoscia Oral pharmaceutical formulation of montelukast and levocetirizine and method for its production
KR102481517B1 (ko) * 2021-08-30 2022-12-27 주식회사 클라시아 약제학적 제제
WO2023068839A1 (ko) * 2021-10-21 2023-04-27 한화제약주식회사 몬테루카스트 또는 이의 약학적으로 허용가능한 염 및 레보세티리진 또는 이의 약학적으로 허용가능한 염을 함유하는 안정성이 개선된 필름코팅 정제
KR20240045586A (ko) 2022-09-30 2024-04-08 주식회사 제뉴원사이언스 레보세티리진 또는 이의 약학적으로 허용가능한 염 및 몬테루카스트 또는 이의 약학적으로 허용가능한 염을 포함하는 안정성이 향상된 이층정 정제 및 그의 제조방법
KR20250005771A (ko) 2023-07-03 2025-01-10 경동제약 주식회사 레보세티리진 및 몬테루카스트를 포함하는 복합 조성물
KR20250081149A (ko) * 2023-11-29 2025-06-05 알리코제약(주) 안정성이 향상된 몬테루카스트 및 루파타딘 함유 조성물 및 이의 제조 방법

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1204580A (en) 1968-10-05 1970-09-09 Aspro Nicholas Ltd Pharmaceutical dosage forms
DK154078C (da) 1981-02-06 1989-05-22 Ucb Sa Analogifremgangsmaade til fremstilling af 2-(2-(4-(diphenyl-methyl)-1-piperazinyl)ethoxy)-acetamider eller syreadditionssalte heraf
US4800162A (en) 1987-04-01 1989-01-24 Sepracor, Inc. Method for resolution of steroisomers in multiphase and extractive membrane reactors
US5057427A (en) 1988-04-07 1991-10-15 Sepracor, Inc. Method for resolution of stereoisomers
GB8827391D0 (en) 1988-11-23 1988-12-29 Ucb Sa Process for preparation of 2-(2-(4-((4-chlorophenyl)phenylmethyl)-1-pipera-zinyl)ethoxy)-acetic acid & its dihydrochloride
GB8827390D0 (en) 1988-11-23 1988-12-29 Ucb Sa Process for preparation of 2-(2-(4-((4-chlorophenyl)phenylmethyl)-1-pipera-zinyl)ethoxy)-acetic acid & its dihydrochloride
DE4209824A1 (de) 1991-09-06 1993-03-11 Schaeffler Waelzlager Kg Waelzlager fuer linearbewegungen
GB9305282D0 (en) 1993-03-15 1993-05-05 Ucb Sa Enantiomers of 1-(4-chlorophenyl)phenylmethyl)-4-(4-methylphenyl)sulphonyl)piperazine
BE1010095A3 (fr) 1996-04-10 1997-12-02 Ucb Sa Procede de preparation de l'acide 2-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl] ethoxy]-acetique et de ses sels.
BE1010094A3 (fr) 1996-04-10 1997-12-02 Ucb Sa Nouveaux [2-(1-piperazinyl)ethoxy] methyle substitues.
DE10007203A1 (de) 2000-02-17 2001-08-23 Asta Medica Ag Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis
DE60115411D1 (de) 2000-04-12 2006-01-05 Merck Frosst Canada & Co Kirkl Verfahren und zusammensetzungen zur behandlung von allergischen zuständen mit pgd2 rezeptor antagonisten
KR100795419B1 (ko) * 2006-01-03 2008-01-17 (주)네오메딕스 암로디핀 및 아스피린을 함유하는 약학 제제
KR100910848B1 (ko) * 2007-09-13 2009-08-06 재단법인서울대학교산학협력재단 알러지성 비염 치료약물을 유효성분으로 함유하는 비강분무용 마이크로스피어 및 이의 제조방법
WO2010107404A1 (en) * 2009-03-16 2010-09-23 Mahmut Bilgic Stable pharmaceutical combinations
KR20130009553A (ko) 2011-07-15 2013-01-23 한미약품 주식회사 몬테루카스트 또는 이의 약학적으로 허용가능한 염 및 레보세티리진 또는 이의 약학적으로 허용가능한 염을 함유하는 캡슐 제제
KR101861307B1 (ko) * 2011-10-13 2018-07-06 한미약품 주식회사 정제를 포함하는 경질 캡슐 복합 제형

Also Published As

Publication number Publication date
US9486528B2 (en) 2016-11-08
PH12014501545A1 (en) 2014-10-08
CN104039314A (zh) 2014-09-10
EP2800558B1 (en) 2018-04-11
PL2800558T3 (pl) 2018-08-31
RU2614382C2 (ru) 2017-03-24
US20140356422A1 (en) 2014-12-04
EP2800558A4 (en) 2015-08-12
CN104039314B (zh) 2017-07-14
TR201807978T4 (tr) 2018-06-21
ZA201405756B (en) 2016-08-31
WO2013103262A1 (en) 2013-07-11
JP2015503579A (ja) 2015-02-02
BR112014016472A8 (pt) 2017-07-04
ES2671428T3 (es) 2018-06-06
HK1200337A1 (en) 2015-08-07
MX2014008059A (es) 2014-10-06
TW201332590A (zh) 2013-08-16
BR112014016472B1 (pt) 2022-03-15
TWI565482B (zh) 2017-01-11
MX354073B (es) 2018-02-12
AR089666A1 (es) 2014-09-10
PT2800558T (pt) 2018-06-05
BR112014016472A2 (pt) 2017-06-13
JP6163165B2 (ja) 2017-07-12
KR20130081013A (ko) 2013-07-16
PH12014501545B1 (en) 2017-09-06
EP2800558A1 (en) 2014-11-12
KR101418404B1 (ko) 2014-07-10
SI2800558T1 (en) 2018-06-29
SG11201403811VA (en) 2014-08-28
RU2014132428A (ru) 2016-02-27

Similar Documents

Publication Publication Date Title
PH12014501545A1 (en) Stable pharmaceutical formulation for oral administration comprising levocetirizine or a pharmaceutically acceptable salt thereof, and montelukast or a pharmaceutically acceptable salt thereof
PH12020551089A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
PH12018501807A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseas
UA109868C2 (ru) Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
PH12014502363A1 (en) N-aryltriazole compounds as lpar antagonists
WO2014028589A3 (en) 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
UA112296C2 (uk) Сухий порошковий препарат, який містить інгібітор фосфодіестерази
MX2015010971A (es) Derivado novedoso de pirazol.
MX2016013529A (es) Derivados de amidas y sales farmaceuticamente aceptables de los mismos, método de preparación de los mismos y aplicación médica de los mismos.
NZ739760A (en) Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same
MY197785A (en) Combinations of lsd1 inhibitors for the treatment of hematological malignancies
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
WO2013147649A3 (ru) ИНГИБИТОРЫ СИГНАЛЬНОГО ПУТИ PI3K/AKT/IKK/NF-kB, ИХ ФАРМАЦЕВТИЧЕСКИ ПРИЕМЛЕМЫЕ СОЛИ И СОДЕРЖАЩИЕ ИХ КОМПОЗИЦИИ ДЛЯ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ ВИРУСНЫХ ЗАБОЛЕВАНИЙ
PH12014501967A1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
MX368903B (es) Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
WO2013112959A8 (en) Antifibrotic compounds and uses thereof
MX2015016425A (es) Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades.
HK1217092A1 (zh) 治疗性化合物及其用途
PH12014502364A1 (en) Substituted pyrazole compounds as lpar antagonists
MX2015007488A (es) Composicion farmaceutica oftalmologica topica que contiene regorafenib.
PH12015502717B1 (en) Anti-fibrogenic compounds, methods and uses thereof
EA029678B9 (ru) Четвертичные соли пиперидиния
WO2013188279A8 (en) Topical ophthalmological pharmaceutical composition containing cediranib
WO2014024013A8 (en) Pseudouridimycin (pum) and its derivates
GR1008380B (el) Φαρμακευτικο σκευασμα περιεχον ενα αντιικο παραγοντα και μεθοδος για την παρασκευη αυτου